In a significant breakthrough for the field of neurodegenerative research, scientists at Mount Sinai have unveiled new, granular details regarding how APOE4—the most potent genetic risk factor for Alzheimer’s disease—actively contributes to brain damage. Through two high-impact studies recently published in the journals Cell and Cell Stem Cell, the team has demonstrated that this gene does far more than predispose individuals to the disease; it actively damages the brain’s delicate vascular system and hampers the organ’s ability to clear away toxic proteins.
For the more than 7 million older adults in the United States currently living with Alzheimer’s, these findings offer a profound shift in perspective. For years, the deterioration of blood vessels in the brain was viewed by many in the medical community as a secondary consequence of the disease—a "wear and tear" effect that occurred as the condition progressed. The Mount Sinai research suggests the opposite: that vascular damage is a primary, biologically active process driven by APOE4 that may, in fact, be reversible.
Mapping the Vascular Impact of APOE4
The first study, published in Cell on September 24, focused on the intricate relationship between APOE4 and the brain’s circulatory system. To investigate this, Mount Sinai scientists constructed a comprehensive single-cell transcriptomic atlas of the human brain’s blood vessels. By synthesizing existing datasets, the team created a detailed map of gene activity across the various cells responsible for maintaining the brain’s vascular network.
The results provided a startling look at the cellular mechanics of neurodegeneration. Researchers discovered that APOE4 fundamentally alters the behavior of pericytes, which are essential cells tasked with stabilizing small blood vessels and maintaining the integrity of the blood-brain barrier. In the presence of the APOE4 gene, these pericytes undergo a pathological transformation, shifting into myofibroblast-like cells that begin producing scar tissue.
This transition triggers a cascade of negative effects, including vascular fibrosis and a marked increase in the accumulation of amyloid-beta proteins around the blood vessels. This buildup creates a physical obstruction that hinders healthy blood flow, creating a hostile environment that encourages further neurodegeneration.
Crucially, the study also provided evidence that this cycle is not necessarily permanent. By blocking TGF-β signaling—a pathway involved in cell communication and tissue remodeling—the researchers were able to restore pericyte coverage and significantly reduce both fibrosis and amyloid accumulation around the vessels. These results were successfully replicated in aged APOE4 mouse models, proving that the vascular damage associated with this genetic variant could be therapeutically addressed.
"Damage to the brain’s blood vessels is not simply a late consequence of Alzheimer’s disease; it is a biologically active process caused by APOE4 that may be reversible," said Joel W. Blanchard, PhD, the study’s corresponding author and an Associate Professor of Neuroscience and Stem Cell Biology and Regenerative Medicine at the Icahn School of Medicine at Mount Sinai. "These findings reveal new therapeutic targets for preserving vascular function and limiting amyloid accumulation."
Braxton R. Schuldt, an MD/PhD candidate and the first author of the Cell study, emphasized the practical implications of these findings. "We show that APOE4 converts blood-vessel support cells into scar-producing cells, causing amyloid or abnormal protein buildup to accumulate around the brain’s vessels. Through our experiments, we were able to block this protein buildup process, revealing possible new therapeutic treatment options and strategies for protecting the brain’s circulation in people at high genetic risk for Alzheimer’s disease."
Utilizing Human miBrains to Uncover Mechanisms
A cornerstone of this research was the use of "miBrains"—sophisticated, three-dimensional human brain tissue models developed by the Mount Sinai team. Grown from induced pluripotent stem cells, these models replicate the complex architecture of human brain tissue, including its intricate network of blood vessels.
By combining the miBrain data with preclinical models, postmortem human brain tissue, and transcriptomic analysis, the researchers were able to bridge the gap between static tissue samples and dynamic biological events. This multi-pronged approach allowed the team to witness the development of vascular abnormalities in real-time, identifying the mechanisms behind the damage long before they reach the severe stages typically seen in postmortem studies. This capability proved vital in identifying potential therapeutic interventions that could be tested for efficacy and safety within a controlled laboratory environment.
APOE4 and the Failure of Cellular Waste Removal
In the second study, published in Cell Stem Cell, the research team turned their attention to another major consequence of APOE4: its role in the accumulation of misfolded proteins. Abnormal protein buildup, such as the accumulation of alpha-synuclein, is a hallmark of both Parkinson’s disease and Lewy body dementia. However, observing these processes in a living human brain has historically been nearly impossible.
The miBrain system provided a unique window into these microscopic events. Because miBrains contain all the major cell types found in the human brain—including neurons, glial cells, and myelin-producing cells—they allowed the researchers to observe how APOE4 influences protein management. The team found that in APOE4-carrying miBrains, there was a significantly higher concentration of abnormal alpha-synuclein compared to control tissues.
The investigation revealed that APOE4 disrupts the internal maintenance of astrocytes, the support cells that are essential for long-term brain health. Specifically, the gene causes cholesterol to accumulate inside these astrocytes, which in turn interferes with their lysosomal waste-disposal systems. When the lysosome—the cell’s "trash compactor"—is impaired, the cell loses its ability to break down and clear alpha-synuclein. As these proteins accumulate, they eventually spread to nearby neurons, forming the toxic deposits that are a primary driver of neurodegeneration.
These findings point toward lipid metabolism and lysosomal function as critical, previously under-explored therapeutic targets for treating both Alzheimer’s and Parkinson’s disease. By identifying the specific chain of events—from APOE4 to cholesterol buildup, to impaired protein clearance, to toxic deposition—the researchers have opened a new pathway for drug development.
A Platform for Personalized Medicine
The utility of the miBrain system extends beyond its ability to model disease; it also offers a path toward personalized medicine. According to Louise Mesentier-Louro, PhD, Assistant Professor of Neuroscience and Stem Cell Biology and Regenerative Medicine at Mount Sinai and first author of the Cell Stem Cell study, the ability to cryopreserve these tissues is a significant technological leap.
"A key advance of our technology is that miBrains with predefined cellular compositions and disease-related factors can be cryopreserved," Dr. Mesentier-Louro explained. "This capability improves reproducibility and scalability of complex disease modeling and supports more efficient drug development and validation."
Looking toward the future, the Mount Sinai team is actively developing miBrains derived from the stem cells of individual patients. This personalized approach could eventually allow clinicians to investigate how neurodegenerative disease progresses differently from one person to the next, as well as predict how a specific patient might respond to a particular treatment regimen.
"At Mount Sinai, we are creating and cryopreserving miBrains from patients," Dr. Blanchard added. "This will enable personalized studies into how neurodegenerative disease develops and how individuals may respond to therapies. By enabling potential therapies to be tested earlier and more efficiently, the miBrain platform could help bridge the gap between laboratory discoveries and treatments for a broad range of disorders."
The research was supported by a variety of organizations, including the National Aeronautics and Space Administration, the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, the Michael J. Fox Foundation for Parkinson’s Research, the CureAlz Fund, and The SWT Foundation. As the scientific community continues to grapple with the complexities of Alzheimer’s and related dementias, these findings provide a vital roadmap for future investigation and the development of much-needed therapeutic interventions.
